Loading...

Inogen, Inc.

INGNNASDAQ
Healthcare
Medical - Devices
$7.75
$0.22(2.92%)

Inogen, Inc. (INGN) Financial Performance & Income Statement Overview

View comprehensive annual and quarterly summaries for Inogen, Inc. (INGN), featuring income statements, balance sheets, and cash flow data.

Revenue Growth
6.35%
6.35%
Operating Income Growth
61.13%
61.13%
Net Income Growth
64.97%
64.97%
Operating Cash Flow Growth
282.87%
282.87%
Operating Margin
-9.60%
9.60%
Gross Margin
43.59%
43.59%
Net Profit Margin
-7.58%
7.58%
ROE
-13.77%
13.77%
ROIC
-13.46%
13.46%

Inogen, Inc. (INGN) Income Statement & Financial Overview

View the income breakdown for Inogen, Inc. INGN across both annual and quarterly reports.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$82.28M$80.08M$88.83M$88.77M
Cost of Revenue$51.89M$43.79M$47.49M$41.62M
Gross Profit$30.39M$36.29M$41.34M$47.15M
Gross Profit Ratio$0.37$0.45$0.47$0.53
R&D Expenses$4.03M$5.90M$3.52M$4.43M
SG&A Expenses$39.99M$41.78M$45.62M$44.19M
Operating Expenses$44.03M$47.67M$49.14M$53.19M
Total Costs & Expenses$95.92M$123.55M$96.63M$94.80M
Interest Income$0.00$1.41M$1.04M$1.33M
Interest Expense$0.00$0.00$0.00$0.00
Depreciation & Amortization$0.00$5.08M$0.00$5.34M
EBITDA-$7.66M-$5.007M-$7.79M-$1.30M
EBITDA Ratio-$0.09-$0.06-$0.09-$0.01
Operating Income-$7.66M-$11.39M-$7.79M-$6.04M
Operating Income Ratio-$0.09-$0.14-$0.09-$0.07
Other Income/Expenses (Net)$1.39M$1.30M$1.73M$1.47M
Income Before Tax-$6.27M-$10.09M-$6.06M-$5.60M
Income Before Tax Ratio-$0.08-$0.13-$0.07-$0.06
Income Tax Expense-$97000.00-$330000.00-$101000.00-$7000.00
Net Income-$6.17M-$9.76M-$5.96M-$5.59M
Net Income Ratio-$0.08-$0.12-$0.07-$0.06
EPS-$0.25-$0.41-$0.25-$0.24
Diluted EPS-$0.25-$0.41-$0.25-$0.24
Weighted Avg Shares Outstanding$25.16M$23.65M$23.75M$23.61M
Weighted Avg Shares Outstanding (Diluted)$25.16M$23.65M$23.75M$23.61M

Over the last four quarters, Inogen, Inc. achieved steady financial progress, growing revenue from $88.77M in Q2 2024 to $82.28M in Q1 2025. Gross profit stayed firm with margins at 37% in Q1 2025 versus 53% in Q2 2024. Operating income totaled -$7.66M in Q1 2025, maintaining a -9% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$7.66M. Net income rose to -$6.17M, with EPS at -$0.25. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;